Metastatic brain tumor following negative second-look operation for ovarian carcinoma

Deutsch, Michael; Beck, Daniel R.; Manor, Dorith; Brandes, Joseph M.

doi:10.1016/0090-8258(87)90238-1

Cited by 28 publications

(16 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the series by Cohen et al [6], patients with grade I and grade II tumors had a median interval of 4.73 years from the diagnosis of primary cancer to the development of CNS involvement, as opposed to a median interval of 1.5 years in patients with grade III tumors (p = .03). This is in agreement with the belief that advanced disease and poorly differentiated tumors at the time of initial diagnosis place a patient at greater risk for CNS metastasis [6,23,30]. In contrast, other investigators reported that the degree of histological differentiation does not seem to be clearly correlated with brain metastasis [24,28].…”

Section: Stage Histopathology and Grade Of Primary Tumorsupporting

confidence: 62%

See 1 more Smart Citation

Brain Metastases from Epithelial Ovarian Cancer: A Review of the Literature

2006

View full text Add to dashboard Cite

Key Words. Brain metastases • Surgery • Stereotactic radiosurgery • Whole-brain radiotherapy • Chemotherapy Learning ObjectivesAfter completing this course, the reader will be able to:1. Select the appropriate treatment strategies for ovarian cancer patients with solitary brain metastases and extracranial disease.2. Describe the most important prognostic factors for ovarian cancer patients with brain metastases.3. List the diagnostic steps needed to establish the diagnosis of brain metastases in ovarian cancer patients.

show abstract

Section: Stage Histopathology and Grade Of Primary Tumorsupporting

confidence: 62%

“…This allows metastases at distant sites to implant and grow. Another explanation is the availability of better imaging techniques for the diagnosis of brain metastases [11,[21][22][23][24]. In addition, chemotherapy may cross the blood-brain barrier (BBB) poorly, yet it increases the propensity for CNS metastases.…”

Section: Incidencementioning

confidence: 99%

Brain Metastases from Epithelial Ovarian Cancer: A Review of the Literature

2006

View full text Add to dashboard Cite

show abstract

“…Traditionally, WBRT has been the accepted standard treatment for most patients with brain metastases and has contributed to improved survival (Kong et al 2010). For patients treated only by the WBRT, the overall median survival time is about 3 -6 months, with approximately 15% of patients alive at 1 year (Anupol et al 2002;Cohen et al 2004;D ' Andrea et al 2005;Deutch et al 1987). Multimodal treatment may improve QoL and outcome, and a signifi cant prolongation in survival can be obtained by surgery in combination with radiotherapy and chemotherapy (Al Barbarawi et al 2005;Micha et al 2004;Monaco et al 2008;Pietzner et al 2009).…”

Section: Discussionmentioning

confidence: 99%

“…Th is mechanism remains unclear (Matsunami et al 1999). Generally, in women, less than 1% of brain metastases are of primary ovarian origin (Deutch et al 1987;Matsunami et al 1999;Ziegler et al 1987), and an incidence of secondary brain metastases in EOC patients ranges from 0.29% to 12% (Anupol et al 2002;Bruzzone et al 1993;Cohen et al 2004;Suzuki et al 1999). Th e aim of the study was to investigate the clinical feature and prognosis in 15 patients with the EOC metastasised to the CNS.…”

Section: Introductionmentioning

confidence: 99%

Central nervous system metastases from epithelial ovarian cancer

Gottwald

Dukowicz

Spych

et al. 2012

Journal of Obstetrics and Gynaecology

View full text Add to dashboard Cite

The aim of the study was to assess the clinical features and prognosis in patients with epithelial ovarian cancer (EOC) metastasised to the central nervous system (CNS). A total of 15 patients were studied retrospectively. Clinical and pathological data and follow-up were analysed. It was found that at the diagnosis of primary EOC, the patients were 41-69 years old (56.6 ± 8.3). The interval from diagnosis of primary EOC until the relapse was 2-39 months (19.1 ± 10.5). Palliative radiotherapy was the treatment of the CNS relapse in 13 patients (86.7%). The follow-up after CNS relapse varied 0.5-15 months (4.7 ± 4.2). At the time of retrospective analysis, none of the patients were still alive. Multifocality of the CNS metastases, the presence of synchronous extracranial metastases and locations in the brain were not associated with survival. It was concluded that the development of the CNS metastases seems to be not uncommon in patients with advanced ovarian cancer. Despite oncological treatment, they are indicators of poor prognosis, and most of the patients do not survive beyond the first year of follow-up.

show abstract

“…In most of the cases with cerebral metastasis, the prognosis is even poorer. Once the brain metastasis develops, the prognosis is very poor; the main therapeutic aim is to palliate and help the patient for a moderate status, and the median survival time is 3–6 months; 15% of patients are alive at the end of a year [14]. The prognosis for patients who have isolated brain metastasis is somehow a bit better than the patients with additional other organ metastasis.…”

Section: Discussionmentioning

confidence: 99%